These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. Shen J; Chan HL; Wong GL; Chan AW; Choi PC; Chan HY; Chim AM; Yeung DK; Yu J; Chu WC; Wong VW Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1057-66. PubMed ID: 23066946 [TBL] [Abstract][Full Text] [Related]
6. Hepatic sonic hedgehog protein expression measured by computer assisted morphometry significantly correlates with features of non-alcoholic steatohepatitis. Estep M; Mehta R; Bratthauer G; Alaparthi L; Monge F; Ali S; Abdelatif D; Younoszai Z; Stepanova M; Goodman ZD; Younossi ZM BMC Gastroenterol; 2019 Feb; 19(1):27. PubMed ID: 30744560 [TBL] [Abstract][Full Text] [Related]
7. Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH. Pimentel CF; Jiang ZG; Otsubo T; Feldbrügge L; Challies TL; Nasser I; Robson S; Afdhal N; Lai M Dig Dis Sci; 2016 Mar; 61(3):905-12. PubMed ID: 26462489 [TBL] [Abstract][Full Text] [Related]
8. Plasma Cytokeratin-18 Level As a Novel Biomarker for Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease. Mandelia C; Collyer E; Mansoor S; Lopez R; Lappe S; Nobili V; Alkhouri N J Pediatr Gastroenterol Nutr; 2016 Aug; 63(2):181-7. PubMed ID: 26835904 [TBL] [Abstract][Full Text] [Related]
9. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. Yilmaz Y; Dolar E; Ulukaya E; Akgoz S; Keskin M; Kiyici M; Aker S; Yilmaztepe A; Gurel S; Gulten M; Nak SG World J Gastroenterol; 2007 Feb; 13(6):837-44. PubMed ID: 17352011 [TBL] [Abstract][Full Text] [Related]
10. Caspase-cleaved keratin-18 fragments increase during alcohol withdrawal and predict liver-related death in patients with alcoholic liver disease. Mueller S; Nahon P; Rausch V; Peccerella T; Silva I; Yagmur E; Straub BK; Lackner C; Seitz HK; Rufat P; Sutton A; Bantel H; Longerich T Hepatology; 2017 Jul; 66(1):96-107. PubMed ID: 28170108 [TBL] [Abstract][Full Text] [Related]
11. Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis. Lee J; Vali Y; Boursier J; Duffin K; Verheij J; Brosnan MJ; Zwinderman K; Anstee QM; Bossuyt PM; Zafarmand MH PLoS One; 2020; 15(9):e0238717. PubMed ID: 32915852 [TBL] [Abstract][Full Text] [Related]
12. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. Feldstein AE; Alkhouri N; De Vito R; Alisi A; Lopez R; Nobili V Am J Gastroenterol; 2013 Sep; 108(9):1526-31. PubMed ID: 23752877 [TBL] [Abstract][Full Text] [Related]
13. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Kowdley KV; Belt P; Wilson LA; Yeh MM; Neuschwander-Tetri BA; Chalasani N; Sanyal AJ; Nelson JE; Hepatology; 2012 Jan; 55(1):77-85. PubMed ID: 21953442 [TBL] [Abstract][Full Text] [Related]
14. Fetuin-A mRNA expression is elevated in NASH compared with NAFL patients. Kahraman A; Sowa JP; Schlattjan M; Sydor S; Pronadl M; Wree A; Beilfuss A; Kilicarslan A; Altinbaş A; Bechmann LP; Syn WK; Gerken G; Canbay A Clin Sci (Lond); 2013 Oct; 125(8):391-400. PubMed ID: 23627434 [TBL] [Abstract][Full Text] [Related]
15. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients. Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434 [TBL] [Abstract][Full Text] [Related]
16. Elevated serum levels of cell death circulating biomarkers, M30 and M65, in patients with β-thalassemia major. Esmaeil N; Moayedi B; Gharagozloo M; Maracy MR Hemoglobin; 2013; 37(4):404-10. PubMed ID: 23600495 [TBL] [Abstract][Full Text] [Related]
17. Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index. Polyzos SA; Kountouras J; Papatheodorou A; Katsiki E; Patsiaoura K; Zafeiriadou E; Papadopoulou E; Zavos C; Terpos E Ann Hepatol; 2013; 12(5):749-57. PubMed ID: 24067262 [TBL] [Abstract][Full Text] [Related]
18. The expression of serum M30 and M65 in chronic hepatitis B patients with non-alcoholic fatty liver disease. Liang J; Han T; Gao YT; Jing L; Ma Z Eur Rev Med Pharmacol Sci; 2015 Nov; 19(21):4123-9. PubMed ID: 26592838 [TBL] [Abstract][Full Text] [Related]
19. Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness. Liebig S; Stoeckmann N; Geier A; Rau M; Schattenberg JM; Bahr MJ; Manns MP; Jaeckel E; Schulze-Osthoff K; Bantel H Clin Transl Gastroenterol; 2019 Aug; 10(8):e00066. PubMed ID: 31397685 [TBL] [Abstract][Full Text] [Related]
20. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Younossi ZM; Jarrar M; Nugent C; Randhawa M; Afendy M; Stepanova M; Rafiq N; Goodman Z; Chandhoke V; Baranova A Obes Surg; 2008 Nov; 18(11):1430-7. PubMed ID: 18500507 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]